Financial Survey: Novo Nordisk A/S (NYSE:NVO) & Cumberland Pharmaceuticals (NASDAQ:CPIX)

Novo Nordisk A/S (NYSE:NVO – Get Free Report) and Cumberland Pharmaceuticals (NASDAQ:CPIX – Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, dividends and analyst recommendations.

Valuation & Earnings

This table compares Novo Nordisk A/S and Cumberland Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Novo Nordisk A/S $46.80 billion 3.97 $15.51 billion $3.97 10.48
Cumberland Pharmaceuticals $44.52 million 1.75 -$2.84 million $4.49 1.16

Novo Nordisk A/S has higher revenue and earnings than Cumberland Pharmaceuticals. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than Novo Nordisk A/S, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Novo Nordisk A/S and Cumberland Pharmaceuticals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Novo Nordisk A/S 5 16 5 0 2.00
Cumberland Pharmaceuticals 1 0 0 0 1.00

Novo Nordisk A/S currently has a consensus price target of $59.44, suggesting a potential upside of 42.89%. Given Novo Nordisk A/S’s stronger consensus rating and higher probable upside, equities analysts clearly believe Novo Nordisk A/S is more favorable than Cumberland Pharmaceuticals.

Profitability

This table compares Novo Nordisk A/S and Cumberland Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Novo Nordisk A/S 33.99% 53.52% 19.49%
Cumberland Pharmaceuticals 274.38% -31.40% -9.38%

Risk & Volatility

Novo Nordisk A/S has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500. Comparatively, Cumberland Pharmaceuticals has a beta of 0.16, indicating that its stock price is 84% less volatile than the S&P 500.

Insider & Institutional Ownership

11.5% of Novo Nordisk A/S shares are owned by institutional investors. Comparatively, 15.5% of Cumberland Pharmaceuticals shares are owned by institutional investors. 0.1% of Novo Nordisk A/S shares are owned by insiders. Comparatively, 42.1% of Cumberland Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Novo Nordisk A/S beats Cumberland Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

About Novo Nordisk A/S

(Get Free Report)

Novo Nordisk A/S is a Danish pharmaceutical company focused on treatments for diabetes, obesity and other serious chronic diseases. Its portfolio includes insulin and other diabetes medicines, as well as obesity treatments such as Wegovy and diabetes treatments such as Ozempic and Rybelsus. The company also develops medicines for rare blood and endocrine disorders, including hemophilia and growth disorders. Its products are sold in markets around the world. Novo Nordisk traces its roots to Danish insulin companies founded in the 1920s; the two organizations that became Novo Nordisk merged in 1989.

About Cumberland Pharmaceuticals

(Get Free Report)

Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company based in Nashville, Tennessee. Founded in 1999, the company develops, acquires and commercializes branded prescription medicines, with a focus on products used in hospital and other acute-care settings as well as treatments for chronic conditions. Its marketed products include Acetadote, an intravenous treatment for acetaminophen overdose; Caldolor, an intravenous ibuprofen product used to treat pain and fever; and Kristalose, a prescription treatment for constipation.

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.